Solara Active Pharma Sciences Limited has informed the Exchange about Copy of Newspaper Publication made on July 26 2025 wherein the Financial Results for the quarter ended June 30, 2025 were published.
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Solara Active Pharma Sciences has submitted to the exchanges copies of newspaper advertisements published on July 26, 2025 in 'Business Standard' and 'Pratahkal', containing the extract of its unaudited consolidated financial results for the quarter ended June 30, 2025 (Q1FY26). The results were approved by the Board on July 25, 2025 and reviewed by statutory auditors Deloitte Haskins & Sells LLP, who expressed an unmodified conclusion. The filing is a routine compliance submission under SEBI Regulation 47 (LODR). Notes accompanying the published results reiterate ongoing corporate actions: the rights issue (Rs. 449.95 crores) whose first call of Rs. 131.25/share fetched Rs. 149.49 crores (used Rs. 115 crores for debt repayment and Rs. 23.27 crores for general corporate purposes), and the proposed demerger of the CRAMS and Polymers business into a new wholly-owned subsidiary, Synthix Global Pharma Solutions Limited (incorporated April 29, 2025).
This is a procedural compliance filing and does not contain fresh financial information beyond what was already filed with the exchanges. Retail investors should look at the detailed Q1 results submitted earlier for actual performance numbers; the main items worth tracking remain the ongoing CRAMS/Polymers demerger and completion of the rights issue conversion.